• 参会报名
  • 会议通知
  • 会议日程
  • 会议门票

首页 > 商务会议 > 医疗医学会议 > 2015第二届中国国际丙型肝炎论坛(CHCF 2015) 更新时间:2015-01-14 14:24:10

2015第二届中国国际丙型肝炎论坛(CHCF 2015)
收藏人
分享到

2015第二届中国国际丙型肝炎论坛(CHCF 2015) 已过期

会议时间:2015-02-07 08:00至 2015-02-08 18:00结束

会议地点:   详细地址会前通知  

会议规模:暂无

主办单位:

发票类型:增值税普通发票 增值税专用发票

行业热销热门关注看了又看 换一换

        会议通知


        On behalf of the organizing committee of the 2nd Chinternational hepatitis C Forum (CHCF), we would like to invite you to this hepatitis C forum. The forum will be held in Hong Kong on 7th-8th February 2015.

        Worldwide, it is estimated that 40 million Chinese suffered from chronic hepatitis C (HCV) infection. Previously, interferon (IFN) - αbased therapy has led to a drastic reduction in liver-related mortality from chronic HCV infection (end-staged cirrhosis and hepatocellular carcinoma). The standard of care (SOC) therapy has been the use of both pegylated IFN- α and ribavirin (RBV) for either 48 weeks (HCV G1, 4, 5, and 6) or for 24 weeks (HCV G2 and 3), inducing sustained virologic response (SVR) rates of 40%-50% in those with G1 and of 70% or more in those with G2 and 3. However, the treatment uptake has been generally low due to numerous side effects and contraindications to IFNα-based regimens. With the availability of cell culture system allowing subgenomic HCV replicons, new potent, pan-genotypic oral direct-acting antiviral agents (DAAs) have been developed.

        The direct-acting antivirals (DAAs) currently in development for treatment of hepatitis C includes NS3/4A protease inhibitors, NS5A protein inhibitors, NS5B (nucleoside-type) polymerase inhibitors and NS5B (non-nucleoside-type) polymerase inhibitors. In US and Europe, SOC has been changed to 12 weeks Sofosbuvir, with PegIFN + RBV or with Simeprevir for G1,4,5,6 and 12 and 24 weeks of sofosbuvir with RBV for G2 and G3. In the near future, one will anticipate the availability of more highly effective, simplified and short duration (8-12 weeks) all oral DAA-based regimens. Notably, by 2015, Sofosbuvir based therapy (with NS5A replication inhibitor such as Ledipasvir or Daclatasvir) or Abbvie Regimen (ABT-450/r-Ombitasvir + Dasabuvir) will become available. 

        For Chinese, one of the burning needs is the lack of clinical study with these new DAAs. This will greatly restrict the understanding of efficacy (different HCV genotype), safety and the administration (such as dosing). For instance, in China, the most urgent medical need is to deal with G1b patients who had advance liver fibrosis and are IFN-ineligible (intolerance to IFN, autoimmune hepatitis and other autoimmune disorders, hypersensitive to pegIFN, decompensated liver diseases, major depression, neutropenia, thrombocytopenia) or IFN-experienced. For treatment-naive subjects, as most of them have G1b with IL28B of CC genotype, one will expect IFN-RBV therapy will remain as the SOC.

        The cost-effectiveness of these DAAs also needs to be understood, taking into consideration of the wide variation of the economic situation of different countries in Asia. Another important limitation is the lack of access to treatment. Even in well-developed countries in Europe and North America, less than one-fifth of patients with HCV infection have received treatment. Reductions in the burden of HCV-related disease at the population level will require removal of existing barriers to HCV education, screening, evaluation and treatment. Therefore, we need to have practical strategies to enhance HCV evaluation, adherence and treatment response. These measures include integrated care based in the hospital, primary or specialty setting, community-based tele-health, nurse-led education, directly observed therapy and peer-support groups and workers. 

        It is the purpose of this hepatitis C forum to provide a platform for all of us to exchange experiences and to be updated on various aspects of chronic hepatitis C infection-diagnosis, pathogenesis and clinical management. Please mark the date and we look forward to seeing you all. 

         

        查看更多

        会议日程

        (最终日程以会议现场为准)


        08:00–08:30

        主题报告(4)

        主持: 陆志蒙侯金林

        08:00 丙型肝炎和肝癌

        Masao Omata, 东京

         

        08:30–10:00

        -慢性丙型肝炎病毒感染的并发症

        主持: 黎锡滔,陈国

        08:30 在丙型肝炎病毒感染肝脏脂肪变性

        成 军,北京

        08:50 对接受治疗的慢性乙型和丙型肝炎患者的肝纤维化改变进行量化

        汪 艳, 广州

        09:10 关于丙型肝炎的异同:丙肝,乙肝和脂肪肝

        范建高, 上海

        09:30 丙型肝炎和肝癌

        邱宗祥, 香港

        09:50 讨论

        10:00–10:15 茶 歇

         

        10:15–10:45

        主题报告(5)

        主持: 孙剑,成军

        10:15 丙型肝炎和肝移植

        Roger S. Williams, 伦敦

        10:45–12:30

        第五节-丙型肝炎病毒和免疫抑制和移植

        主持: 梁宪孙,DarrellCrawford

        10:45 肝移植后的丙肝管理

        冯恩裕, 香港

        11:05 丙肝和艾滋病

        任永昌, 香港

        11:25 肝癌的全身治疗

        杨明明, 香港

        11:45 讨论

        12:30–13:30

        主题报告(6)

        主持: Shiv K. Sarin, 廖家杰

        12:30 慢性丙型肝炎感染的临床研究-最新的研究成果是什么?

        Stefan Zeuzem, 法兰克福

        13:3015:30

        第六节在DAAs时代治疗慢性丙型肝炎的新对策

        主持: Raymond Schinazi, 高嘉宏

        13:30 吉利德

        14:00 艾伯维

        14:30 强生

        15:00 讨论

        15:30–16:00

        总结,颁奖,记者会

         

        查看更多

        会议门票


        参会费用:

        Registrations open:   Saturday 1st November 2014
        Registrations close:   Saturday 31th January 2015

         

        Registration

        Price (GST incl)

        Delegates

        US $200.00

        Additional Exhibitor

        US $150.00

        查看更多

        会议场地:

        温馨提示
        酒店与住宿: 为防止极端情况下活动延期或取消,建议“异地客户”与活动家客服确认参会信息后,再安排出行与住宿。
        退款规则: 活动各项资源需提前采购,购票后不支持退款,可以换人参加。

        会议支持:

        • 会员折扣
          该会议支持会员折扣
          具体折扣标准请参见plus会员页面
        • 会员返积分
          每消费1元累积1个会员积分。
          仅PC站支持。
        • 会员积分抵现
          根据会员等级的不同,每抵用1元可使用的积分也不一样,具体可参见PLUS会员页面。 仅PC站支持。

        部分参会单位

        主办方没有公开参会单位

        邮件提醒通知

        分享到微信 ×

        打开微信,点击底部的“发现”,
        使用“扫一扫”即可将网页分享至朋友圈。

        录入信息

        请录入信息,方便生成邀请函